| __timestamp | MiMedx Group, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12665000 | 3243000 |
| Thursday, January 1, 2015 | 20202000 | 2472000 |
| Friday, January 1, 2016 | 32407000 | 2548000 |
| Sunday, January 1, 2017 | 35219000 | 19623000 |
| Monday, January 1, 2018 | 36386000 | 30421000 |
| Tuesday, January 1, 2019 | 43081000 | 32793999 |
| Wednesday, January 1, 2020 | 39330000 | 28304000 |
| Friday, January 1, 2021 | 43283000 | 620000 |
| Saturday, January 1, 2022 | 48316000 | 755000 |
| Sunday, January 1, 2023 | 54634000 | 1322000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding cost structures is crucial. This analysis compares the cost of revenue for Viridian Therapeutics, Inc. and MiMedx Group, Inc. over the past decade. From 2014 to 2023, MiMedx Group consistently outpaced Viridian in cost of revenue, peaking at approximately $54.6 million in 2023, a 330% increase from 2014. In contrast, Viridian's costs fluctuated, with a notable spike in 2019 reaching $32.8 million, before dropping significantly in subsequent years. This volatility reflects Viridian's strategic shifts and market challenges. By 2023, their cost of revenue was just $1.3 million, highlighting a dramatic reduction. This comparison underscores the diverse financial strategies and market responses of these two companies, offering insights into their operational efficiencies and market positioning.
Cost of Revenue: Key Insights for GSK plc and Viridian Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Viatris Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Analyzing Cost of Revenue: Pharming Group N.V. and MiMedx Group, Inc.
Cost of Revenue Comparison: Cytokinetics, Incorporated vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Viridian Therapeutics, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Viridian Therapeutics, Inc.